# Cure Ventures

> Cure Ventures is a VC fund backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Newport Beach, United States
- Total investments: 11
- Last investment: Apr 2026
- Lead investor: 82%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/cure-ventures
- Website: https://curevc.com/

Cure Ventures is a venture firm focused on investing in the life sciences and medical technologies. We aim to propel novel cures to market by discovering and enabling biotechnology, pharmaceutical, medical device, and medtech firms with exceptional growth potential committed to addressing unmet medical needs for global patient targets.

## Contacts

5 contacts available for Cure Ventures. Shizune tracks 2 team members at Cure Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cure-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 27% |
| Health Care | 2 | 18% |
| Medical | 1 | 9% |
| Wellness | 1 | 9% |
| Biopharma | 1 | 9% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 27% |
| Seed | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James E. Vath | Partner | 0 | https://shizune.co/investors/profile/james-e-vath |
| Lou Tartaglia | Managing Partner and Co-Founder | 0 | https://shizune.co/investors/profile/lou-tartaglia |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. | $106M | Series A | Apr 21, 2026 |  |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. | $106M | Series A | Apr 21, 2026 |  |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. |  | Seed | Apr 21, 2026 |  |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. |  | Seed | Jun 01, 2025 |  |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. |  | Seed | Jun 01, 2025 |  |
| Tasca | Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications. | $48.1M | Series A | Dec 10, 2024 |  |
| Tasca | Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications. | $48.1M | Series A | Dec 10, 2024 |  |
| Red Arrow Therapeutics | Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency. | $55M | Series A | Sep 18, 2024 |  |
| Clasp Therapeutics | Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M | Series A | Mar 20, 2024 |  |
| Kenai Therapeutics | Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's. | $82M | Series A | Feb 29, 2024 |  |

10 of 11 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 4 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 2 deals together
- [Alaska Permanent Fund](https://shizune.co/investors/profile/alaska-permanent-fund) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [AN Ventures](https://shizune.co/investors/profile/an-ventures) — VC Fund, 2 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cure Ventures invest in?

Cure Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cure Ventures?

Public channels for Cure Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cure Ventures?

The team at Cure Ventures includes James E. Vath (Partner) and Lou Tartaglia (Managing Partner and Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co